I focus on the microcap space (market cap below $250 million) because it is one of the most inefficient and "alpha rich" areas of the global equity market, which provides the greatest opportunity to generate alpha through fundamental research.
I use a bottom up, investment decision making process. The ideal investment has an asymmetric risk/return profile with a limited downside (e.g. high net cash balance, strong cash flow) and significant upside (e.g. asset value extraction, overlooked business model transition).
Microcaps are particularly attractive to the following groups:
Activist investors. A small absolute investment (on a dollar basis) can be leveraged into a relatively large position (as a percentage of shares outstanding), which provides a greater ability to demand change.
Private equity firms. The persistent microcap discount can be “arbed away” via an LBO with the new owners accruing all of the gains for themselves. The small absolute size of many microcaps on an EV basis significantly expands the number of firms able to pursue this strategy.
This inefficiency exists for several reasons.
A lack of analyst coverage due to lower trading volume (less soft dollars from HF/MF), the global settlement that permanently severed the link between research/banking and the rise in electronic trading/decimalization. Moreover, none of these trends are likely to reverse for the foreseeable future (if ever).
A lack of institutional products given the natural capacity constraint for new/existing managers.
An inability to effectively implement a passive approach (e.g. ETFs, index funds) due to the lower liquidity and wider bid/ask spread. However, each of these obstacles can be overcome by using a combination of electronic trading tools (e.g. algos) and patience in building a positive size.
Inaccurate and persistent misconceptions about microcaps (e.g. they are riskier than larger cap stocks).
I currently trade for my personal account but would like to move into the investment management side of the industry.
PLEASE SEE WEBSITE FOR FULL DISCLAIMER: WWW.PUMPSTOPPER.COM
I produce high quality, original research free of charge for the public good. Please see the website for more information, and subscribe to The Pump Stopper email list to receive free, high quality research reports before the rest.
I am always committed to publishing the accurate truth. If you are involved with a company that has been mentioned in a report and find any factual errors, please submit a dispute to Seeking Alpha and it will be reviewed.
If you have any tips on companies misleading investors, please submit them on The Pump Stopper website. I always welcome collaboration and have absolute respect for your anonymity. There are multiple ways to submit documents anonymously, as outlined on the website, and I strongly recommend you send information this way.
And remember to always invest wisely.
I am an activist investor in US and Chinese stocks. I was previously an investment banker in New York Hong Kong and London for 9 years, focused on Equity Capital Markets. I look at both long ideas and short ideas and typically focus on a small number on names where I can spend the time to conduct very deep research. I spend my time living between Los Angeles and Beijing, China.
My focus is on companies that fly under the radar but offer opportunities for investment success because these companies have built in catalysts, a management team that has a clear business plan and fundamentals in place for the catalysts to bear fruit.
My investments include well known stocks, but I write mostly about small cap or under followed stocks. I don't think that a portfolio should be built on solely the type of stock that I write about but I offer ideas for the part of a portfolio dedicated to catalytic investment.
I look for large hedge fund interest in relatively unknown companies and then research the underlying reason for this investment. Most often, the reason is a growth in market share and there is an underlying catalyst.
Team of hardcore quantitative researchers (i.e quants) that comb through academic research and perform historical backtests to generate unique insights into US equities for investors and firms that don't have access to their own in-house quant team. We've packaged our ideas and algorithms into an easy to use, web application software called QuantifiedAlpha.com. This software provides data and predictive analytics on over 3,000 US equities. It bridges the gap between financial academia and mainstream investing, at an affordable price.
Search up a stock on www.QuantifiedAlpha.com, and see what the quant algorithms indicate about its future direction.
Wall Street Breakfast, Seeking Alpha's flagship daily business news summary, is a one-page summary that gives you a rapid overview of the day's key financial news. It's designed for easy readability on the site or by email (including on mobile devices), and is published before 7:00 AM ET every market day.
Wall Street Breakfast readership of over 900,000 includes many from the investment-banking and fund-management industries.
Sign up here to receive the Wall Street Breakfast in your inbox every business day: http://seekingalpha.com/account/email_preferences
I'm a young private investor. I prefer concentrated bets on small, quality businesses. I'm a strategic generalist, tactical specialist; I scan broadly looking for quirky things to become obsessed with for awhile, to accumulate clusters of competence in neglected niches. I'll place on my watch-list most anything that is predictable enough to value accurately, and wait for the right price. My idea horizons, which used to be ~1 year, seem to be lengthening.
My current top holdings are FN, KTCC, AGM, NVMI, EMAN, SILC, and SLP.
Former broker, now an independent analyst/writer on Seeking Alpha and founder and editor of the Growth Stock Forum. Focusing on small-cap, mid-cap and biotech stocks. Looking for substantial sales and earnings growth potential and seeking the best risk-adjusted returns from my stock selection. Taking advantage of medium to long-term momentum.
My articles represent my personal opinion and analysis and should not be regarded as investment advice in any way. Readers and subscribers should do their own due diligence and/or consult their financial advisor before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal.
Exclusive research: http://seekingalpha.com/author/oneil-trader/research
Martin Vlcek is a full-time investor and analyst who has been actively investing and managing money for more than 15 years. Martin has an Economics degree. He currently works for an asset management company BH Securities. Ideas and information expressed in his articles on SeekingAlpha are his own and don't represent an official BH Securities opinion. Martin’s investment philosophy is to hold a truly diversified portfolio of investments across asset classes with low or negative correlation and a positive carry if possible. His primary stock investment focus is on undervalued stocks with upcoming catalysts and a favorable reward-to-risk ratio.
Martin became a full-time investor and money manager after a 15-year career in online marketing where he was one of the pioneers of the pay-per-click search. Martin later held managerial positions at several Fortune 500 companies and also managed his own startup company.
IMPORTANT DISCLAIMER: Martin is not a Registered Investment Advisor, Broker/Dealer, Securities Broker or Financial Planner. The Information in his articles, his comment and his premium subscription service on SeekingAlpha.com or elsewhere is provided for information purposes only. The Information is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any individual. Before using Martin's information to make an investment decision, you should seek the advice of a qualified and registered securities professional and undertake your own due diligence. None of the information provided by Martin is intended as investment advice, as an offer or solicitation of an offer to buy or sell, or as a recommendation, endorsement, or sponsorship of any security, company, or fund. Martin is not responsible for any investment decision made by you. You are responsible for your own investment research and investment decisions.
We are a team of market professionals with 18 years combined experience as investment advisers and stock analysts. We specialize in the transportation sector (rails, air freight, ports, shipping and logistics). We use our deep knowledge about this space to help readers earn higher risk adjusted returns. In addition, we have 11 years of experience trading options and use these to generate extra income. A client with a $100,000 dollar portfolio can expect an extra $3,000 to $8,000 from these investments.
Copperfield Research is the pseudonym of a research team focusing on publicly traded equities. As of the publication date of our articles, we may have long or short equity positions in the companies covered. We do not discuss unpublished reports, or provide any advanced warning of future reports to others. Due to the danger of retaliation, our reports are written under a pseudonym. Please read our Disclaimer on the front page of every opinion piece before reading any of the material.
Tech Analyst and opportunistic investor focused primarily on micro caps and up and coming technology companies. I am currently in discussions with a partner to develop and launch a investment premium newsletter website. If you are interested in learning more about my premium newsletter or would like to be added to my mailing list you can inbox me.
You can follow my personal trades and invest your own money with me via Instavest www.instavest.com My focus is on ground breaking technology and the companies that will deliver them in the future. I have managed a family portfolio since 2008 that has been focused on growth and income generation. You can follow me on twitter @MattMargolis24
Gotham City Capital is a private, biotech research company. Our main objective is to provide investors with low-risk, high reward biotech investments and trades. We place the utmost emphasis on small cap bios that specialize in the most promising therapies out there. In our articles, we will aim to be very specific in our strategy, whether it be a catalyst run-up trade, swing trade or long-term investment. We strive to offer consistent opportunities for investors to create high returns on our biotech picks.
With approximately six year of studies, we feel that we have an excellent balance of expertise between trading, company financing, company management and most specifically, trial data. A solid track record of successfully finding the best trades and companies has driven us to start this company. We believe in making decent size bets on the best companies.
For real time market commentary, make sure to follow Gotham City Capital on Twitter.
I work on the crossroads of design, branding, consumer research and product development. Occasionally, I buy shares of companies, whose industry I understand or work in.
However, I take capitalism and its machinations with the necessary spoonful of quality Swedish stone salt.
The author is presently a full-time private investor focused on investing in public companies. The author has over ten years of financial services experience, which includes long and short bottoms up fundamental buy-side research, private equity, M and A Advisory, and accounting.
See SA policy on anonymous authors: http://seekingalpha.com/page/policy_anonymous_contributors
In no event will the author writing under the pen name Research and Value (hereafter referred to as R&V) or any affiliated party be liable for any direct or indirect trading losses caused by any information published by R&V. Use of the author’s articles is at your own risk. You should do your own research and due diligence and consult with your own advisers before making any investment decision with respect to securities discussed in articles published by the author.
No publication made by R&V is an offer to sell or a solicitation of an offer to buy any security, nor shall any security be offered or sold to any person, in any jurisdiction in which such offer would be unlawful under the securities laws of such jurisdiction. R&V is not registered as an investment advisor in the United States or has similar registration in any other jurisdiction.
R&V strives to provide accurate and reliable information contained in its articles, however no-one is error free and R&V is not responsible for any errors, omissions, or accuracy of any and all information presented in its articles. All information is presented “as is,” without warranty of any kind, whether express or implied. R&V makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any information or with regard to the results to be obtained from its use. All expressions of opinion are subject to change without notice, and R&V does not undertake to update or supplement its articles or any of the information contained therein.
The goal as everyone knows, is to buy good stocks at a discount and sell-short overvalued stocks when they are at a premium. I have a background in business and deal with internal models, analysis, sales pitches and ad information daily. In my downtime, I am enthusiastic about the markets highs, lows and volatility. I believe in real lags between market and business reactions, with the former often in advance of the latter, and vice versa. I look to call manic enthusiasm with a distinct opportunity to go short. A change in sentiment is all it takes. I research fundamentals while scavenging for value.
Mr. Rosenman has nearly 15-years executive experience in the health and wellness sectors, including weight loss, cosmetics skincare and nutrition, both Rx and OTC. Expertise areas include strategic market and product planning and corporate development (evaluation, recommendation and execution of strategic alliances and acquisitions). A MBA graduate of the Sweigart School of Business at Rider University, Rosenman devotes a portion of time back to the collegiate community as a graduate-level adjunct professor for healthcare marketing, consumer behavior and strategic planning. He has several published works in the field of U.S health and wellness, including a focus on how nutritional ingredients will transition into Rx space, specifically with lipid and herbal managment. His current professional role is with one of the fastest growing nutritional companies in the U.S., which also produces Rx and OTC products. He has served as an advisory board member to various organizations in the healthcare field, from venture start-ups to top global enterprises. Mr. Rosenman is a Senior Advisor with Guidepoint Global and is called upon by large institutional investors for insight and expert opinion on healthcare market opportunities (to date he has advised on more than $2 billion USD of related transactions/funding).
Finance professional with more than 15 years of experience in traditional portfolio management and alternative investments. Contrarian in style, focusing on producing yield on a consistent basis.
I started his career as a bond manager for "BPER" in Italy, then leaving for Asia to work as event-driven analyst for "BFIT", active in the arbitrage space and spotting turnaround situations. At the beginning of the new millennium I moved to Switzerland. At "Banca Commerciale Italiana (Suisse)" I became head of US Equity Research and started the fund of hedge funds business of the company. Later I have been covering frontier emerging markets for a Global Macro hedge fund before managing the listed portion of the "Oak Fund" (a Cayman-based offshore fund). In 2007 I was appointed as Head of Global Strategy at "Fideuram Bank Suisse", in charge of multi-asset discretionary mandates.
Today I am independent asset allocator for institutional investors. I focus my attention on areas such as commodities, closed-end funds and emerging markets.
Since 1994 I have been a regular contributor to various financial magazines in Italy (such as "Borsa & Finanza" and "Il Mondo") and speaker at investment conferences around the globe.
My views on the markets are published at globallocator.blogspot.com.
Adam Gefvert is the head researcher for White Diamond Research, a research firm for hedge funds and high net worth individuals. Primarily a short seller, he has saved investors millions of dollars by exposing highly overvalued small cap stocks. He has a 90%+ success rate with his Seeking Alpha short ideas. He specializes in technology, energy, and biotech stocks, because those are the sectors with the greatest valuation inefficiencies.
You can follow Adam on twitter @shiningboy
At Valuentum, we think the best opportunities arise from a complete understanding of all investing disciplines in order to identify the most attractive stocks at any given time. Valuentum therefore analyzes each stock across a wide spectrum of philosophies, from deep value through momentum investing. We think companies that are attractive from a number of investment perspectives--whether it be growth, value, momentum, etc.--have the greatest probability of capital appreciation and relative outperformance. The more investors that are interested in the stock for reasons based on their respective investment mandates, the more likely it will move higher.
Please read our Disclaimer that applies to all articles published on Seeking Alpha: http://www.valuentum.com/categories/20110613
Follow us on Twitter: @Valuentum